Treg based therapies have become a research
hotspot in the field of immunotherapy due to their ability to prevent / delay graft
rejection and control autoimmune responses generated post adoptive transfer in
vivo
Roots Analysis has
announced the addition of “Regulatory T-Cell (Tregs) Therapies Market,
2021 – 2035” report to
its list of offerings.
The report features an extensive study of the current market landscape,
offering an informed opinion on the likely adoption of these therapies over the
next decade. It features an in-depth analysis, highlighting the capabilities of
various stakeholders engaged in this domain. In addition to other elements, the
study includes:
§ A
detailed assessment of the current market landscape of drug developers engaged
in the development of regulatory T-cell therapies.
§ A
detailed analysis of more than 180+ completed, ongoing and planned clinical
studies of regulatory T-cell therapies.
§ Detailed
profiles of developers of regulatory T-cell therapies (shortlisted on the
basis of the number of pipeline products).
§ An
analysis of the partnerships that have been established in this domain, in the
recent past.
§ A
detailed analysis of various investments undertaken by companies in this
domain.
§ A detailed market forecast, featuring
analysis of the current and projected future opportunity across key market
segments (listed below)
§ A detailed overview of the current market
landscape of Treg cell therapies, along with information on several relevant
parameters, such as type of product (Tregs, interleukin 2, monoclonal
antibodies, small molecules and others), phase of development (preclinical /
discovery, phase I, phase I/II, phase II, phase II / III and phase III),
therapeutic area (autoimmune disorders, oncological disorders, post-transplant
infection, neurological disorders, metabolic disorders, dermatological disorders, infectious
diseases, and others), target indication (diabetes mellitus, graft vs host
diseases, post liver transplant infection, post kidney transplant infection,
amyotrophic lateral sclerosis, multiple sclerosis, myelodysplastic syndromes,
atopic dermatitis and acute myeloid leukemia), source of T-cells (autologous and allogeneic), route of administration (intravenous,
subcutaneous and intramuscular), dose frequency (multiple dose and single
dose), target patient segment (children, adults and elderly patients), type of
therapy (monotherapy and combination therapy) and type of developer (industry
and non-industry). In addition, it presents details of the companies developing
Treg cell therapies, highlighting their year of establishment, company size,
location of headquarters and most active players (in terms of number of
pipeline candidates).
- Tregs
- Interleukins
- Small molecules
§ Target
Indication
- Crohn’s
Disease
- Bipolar
Disorder
- Allergic
Rhinoconjunctivitis
- COVID 19
- Diabetes
Mellitus
- Systemic
Lupus Erythematosus
- Alzheimer’s
Disease
- Graft Vs
Host Disease
§ Key
Geographical Regions
- North
America
- Europe
- Asia Pacific
Key companies covered in
the https://www.rootsanalysis.com/reports/regulatory-t-cell-therapies-market.html
§ Abata Therapeutics
§ Cellenkos
§ Coya Therapeutics
§ ILTOO Pharma
§ NEKTAR
§ Roche
§ Sonoma Biotherapeutics
§ TeraImmune
§ TRACT Therapeutics
For more information please
click on the following link:
https://www.rootsanalysis.com/reports/regulatory-t-cell-therapies-market.html or
email [email protected]
Other Recent Offerings
1.
CD47 Targeting Therapeutics Market: Industry Trends and Global
Forecasts, 2021-2030
2.
Antibody Drug Conjugates Market
(6th Edition): Industry Trends and Global Forecasts, 2021-2030
3.
Novel T-Cell Immunotherapies Market: Industry Trends and Global Forecasts,
2021-2030
4.
TIL-based Therapies Market: Industry Trends and Global Forecasts,
2021-2030
5.
Peptide Therapeutics Market: Industry Trends and Global
Forecasts, 2021-2030
6.
CRISPR Based Therapeutics Market: Focus on Cartridges, Syringes and
Vials
7.
(2nd Edition),
2021-2030
Key Questions Answered
§ What are the prevalent
R&D trends related to Treg cell therapies?
§
Which are the key therapeutic areas currently being targeted by Treg
cell therapies?
§
What are the key challenges faced by stakeholders engaged in this
domain?
§
Who are the leading industry and non-industry players engaged in the
development of Treg cell therapies?
§
What are the key geographies where research focused on Treg cell
therapies is being conducted?
§
What are the key value drivers that are likely to influence the
evolution of this upcoming market?
§ How is the current and
future market opportunity likely to be distributed across key market segments?
About Roots Analysis
perspectives in the bio-pharmaceutical industry. The in-depth research,
analysis and insights are driven by an experienced leadership team which has
gained many years of significant experience in this sector. If you’d like help
with your growing business needs, get in touch at [email protected]
Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
